Genocore-Biotech.com Announce Collaboration Agreement to Develop and Commercialize Multiple Sclerosis Therapy (MST)
Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody.
<p><strong>Shenzhen; 22, December 2015:</strong> Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs, today announced that they have entered into an exclusive collaboration and license agreement to develop and commercialize a multiple sclerosis (MS) therapy. The therapy is a novel, oral sustained-release compound being developed to improve walking ability in people with MS. The parties have also entered into a related supply agreement.</p> <p> </p> <p align="center"><img title="logo Genocore-Biotech-com" src="http://oi67.tinypic.com/20gmlvp.jpg" alt="logo Genocore-Biotech-com" /></p> <p align="/center">Under the terms of the agreement, <strong><a title="Genocore" href="http://genocore-biotech.com/en/">Genocore</a></strong> Biotech will commercialize the medicine on markets worldwide and will also have responsibility for regulatory activities and future clinical development of in those markets. Genocore Biotech will make tiered, double-digit royalty payments to its partner sales including royalties owed. The parties can also carry out future joint development activities under a cost-sharing arrangement.</p> <p>“Genocore Biotech has outstanding capabilities in commercializing neurology and oncology products and is known globally for its reputation as an innovative company in the field of multiple sclerosis. We believe that our international expertise in MST and neurology also will help us optimize future development of MST and maximize its value in all markets.”</p> <p>“As we look to expand our global MST experience, we believe that this new treatment has the potential to become an important oral therapy that may help improve the walking ability of a wide range of patients – including patients with relapsing forms of MS, as well as primary and secondary progressive MST.” said Mr. Wang Yen Horng, president and CEO of Genocore Biotech.</p> <p><strong>About Genocore Biotech:</strong></p> <p><strong><a title="Genocore-Biotech.com" href="http://genocore-biotech.com/en/">Genocore-Biotech.com</a></strong> is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs. With a total investment of about 95 million USD, about 110 employees and R&D lab, Process Development lab, Analytical & Quality center, and a cGMP clinical production facility the firm is a respectable player in the medical industry. Genocore Biotech has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development. They have on average 15-20 years of hand-on working experience at leading western biopharmaceutical companies.</p> <p><strong>For Media Contact:</strong></p> <p>Company: Genocore-Biotech.com</p> <p>Address: Excellence Century Plaza</p> <p>Tower 1, Fuhua 3rd Road, Futian District</p> <p>Shenzhen, People's Republic of China</p> <p>Tel: +86 755 330 595 45</p> <p>Email: email@example.com</p>